1003-93 Outcomes prediction with continuous 12-lead ST-segment recovery in ST elevation myocardial infarction: Similarities or differences with thrombolytic versus direct stenting populations?  by Krucoff, Mitchell W et al.
JACC March 3, 2004 ABSTRACTS - Myocardial Ischemia and Infarction  247A
M
yocardial Ischem
ia and Infarction
1003-90 Successful Embolization Protection Using GuardWire 
System for Acute Myocardial Infarction: Multicenter 
Registry in Japan
Sunao Nakamura, Mizuki Hirose, Takanori Miyauchi, Akihiko Kanazawa, Koji Hozawa, 
Hitoshi Nakamura, Kazutoshi Yamamoto, Osamu Hirashima, Nobuyuki Makishima, Noriki 
Kutsukata, Shotaro Nakamura, Jun Koyama, New Tokyo Hospital, Matsudo, Japan, 
Kasori Hospital, Chiba, Japan
Background: Distal embolism is one of the major complications during percutaneous
coronary intervention (PCI) for acute myocardial infarction (AMI). These complications
may be potentially mitigated by distal protection. The GuardWire system (GS) consists of
an occlusion balloon which is inflated distally allowing ‘protected’ PCI has recently
become available. Aim: To evaluate the efficacy and safety of this device, we studied a
total of 212 patients (male 69.8%) of AMI who underwent PCI using GS. The GS was
successfully placed in all of the cases. Gross inspection of the filter after retrieval demon-
strated macroscopic emboli including thrombus in 93.9% of patients. Results: See table.
Conclusion: The preliminary results suggest that PCI for AMI using GS is technically
feasible, safe and early clinical outcomes appear to be favorable. 6 months and 1 year
follow-up clinical outcome will be available at time of presentation.
1003-91 Evolution of Thrombolysis in Myocardial Infarction 
Myocardial Perfusion Grade During Primary Coronary 
Angioplasty in Acute Myocardial Infarction Predicts 
Long-Term Recovery of Left Ventricular Function
Jaroslaw Zalewski, Krzysztof Zmudka, Piotr Musialek, Cafer Zorkun, Andrzej Kadzielski, 
Wojciech Zajdel, Jagiellonian University, Krakow, Poland
Background: TIMI myocardial perfusion grade (MPG) reflects the integrity of microvas-
culature. We hypothesized that a combined analysis of MPG before and after PCI in AMI
may reveal information on further recovery of left ventricular (LV) function. Methods: We
evaluated 585 consecutive patients (pts, age 58,7±11 y) with ST-segment elevation AMI
treated with PCI. Myocardial injury was expressed as area under the curve of CK-MB
release in the first 48 hours (AUC). MPG was evaluated before and after PCI. The sum of
ST-segment elevation (12-lead ECG) was obtained before and 30 minutes after PCI. LV
Ejection fraction (EF) was evaluated by 2D echocardiography at 24 hours and 6 months
after PCI. Results: Evaluation of MPG before and after PCI showed 6 different reperfu-
sion patterns; I - MPG-0/1 before and after PCI, II - severe MPG deterioration (from 2/3 to
0/1), III - MPG improvement from grade 0/1 to 2, IV - mild MPG deterioration (from 2/3 to
2), V - MPG improvement from 0/1 to 3, VI - high MPG maintained (2/3 before and 3 after
PCI). Results for AUC, proportion of pts with complete (>70%) ST resolution, and EF at
24h and 6mo by the reperfusion pattern are shown in the table. Concusion: Maintaining
a high MPG throughout PCI in AMI or achieving a marked MPG improvement are both
related to a mild, largely reversible, myocardial injury and implicate recovery of LV func-
tion. In contrast, lack of improvement of a poor MPG or severe deterioration of MPG are
associated with a major myocardial injury and lack of LV function recovery at 6 months.
1003-92 Relationship Between Acute Hyperglycemia and 
Microvascular Injury After Primary Coronary 
Angioplasty for Acute Myocardial Infarction
Takefumi Takahashi, Yoshikazu Hiasa, Takeshi Tomokane, Koji Yamaguchi, Riyo Ogura, 
Hitoshi Miyajima, Yoshikazu Ohara, Tatsuro Ogata, Kenichiro Yuba, Naoki Suzuki, 
Shinobu Hosokawa, Koichi Kishi, Ryuji Ohtani, Tokushima Red Cross Hospital, 
Komatsushima, Japan
Background: Previous studies have reported that acute hyperglycemia is associated
with adverse outcomes after acute myocardial infarction (AMI). The aim of this study was
to examine the relationship between acute hyperglycemia and microvascular injury after
primary coronary angioplasty for AMI. Methods: We studied 106 patients with a first
anterior wall AMI who underwent primary coronary angioplasty within 12 h of onset. Cor-
onary flow velocity parameters were assessed immediately after reperfusion using a
Doppler guidewire. We evaluated the presence of systolic flow reversal (SFR), diastolic
deceleration time (DDT), and coronary flow reserve (CFR) as markers of microvascular
injury. We defined severe microvascular injury as the presence of SFR and DDT <600
ms. Results: Acute hyperglycemia, defined as a blood glucose level of >190 mg/dl at
admission, was found in 35 patients (33%). In patients with acute hyperglycemia, the
presence of SFR was more frequent, DDT was shorter, and CFR was lower. By regres-
sion analysis, the blood glucose level significantly correlated with DDT (r=0.43,
p<0.0001). Multivariate analysis showed that acute hyperglycemia was an independent
determinant of severe microvascular injury (odds ratio 7.36, p=0.015). Conclusions:
Acute hyperglycemia is related to severe microvascular injury, resulting in larger infarct
size and worse left ventricular function. This may partly account for adverse outcomes
after AMI in patients with acute hyperglycemia.
1003-93 Outcomes Prediction With Continuous 12-Lead ST-
Segment Recovery in ST Elevation Myocardial 
Infarction: Similarities or Differences With Thrombolytic 
Versus Direct Stenting Populations?
Mitchell W. Krucoff, Cindy L. Green, Suzanne W. Crater, Ricardo Baeza, Galen Wagner, 
Per Johanson, Duke University Medical Center, Durham, NC
Background:ST segment recovery reflects the speed, stability and quality of microvas-
cular reperfusion in STEMI pts, and is highly predictive of clinical outcome. The relative
comparability of this biomarker between reperfusion with lytic therapy vs. mechanical
reperfusion with stenting, however, has never been reported.
Methods: Retrospective database review of a total of 21,223.4 hrs including 1,273,404
12-lead ECGs from 24 hr/pt digital ST-segment monitoring of 877 STEMI pts, 320 treated
with primary stenting and 557 with lytic therapy compared Duke eECG Core Laboratory
endpoints: 1) time to stable ST recovery (STABLE), as >50% recovery from peak ST lev-
els lasting >4 hrs (minutes); 2) extent of ST recovery (>70%ST) as >70% recovery from
peak ST levels at STABLE (%yes); 3) 3 hr ST deviation vs. time trend curve area (AREA)
in uV-min; 4) late ST re-elevation (LATE) of >150uV over baseline after STABLE (%yes).
Mortality and major adverse cardiovascular endpoints (MACE) of death, re-MI, new CHF
and urgent CABG were defined by each trial’s coordinating center, blinded to ST data.
Core lab ST analyses were blinded to outcomes.
Results: MACE of 13.3% and 17.2% was seen with lytics and stenting, respectively. ST
endpoints were: 
Conclusions:Considering differences in pt population size in stent and lytics groups, 
continuous ST-segment recovery endpoints are essentially equally predictive of outcome 
in STEMI pts undergoing either medical or mechanical intervention.
AMI (n=212)
Characteristics of AMI
 Culprit: anterior location (%) 54.2
 Cardiogenic shock (%) 19.8
 Forester III, IV (%) 26.4
 Peak CPK (mean) 2010
Clinical outcome
 Procedural success (%) 100
 Clinical success (%) 100
 No flow (%) 0
 TIMI 3 post PCI (%) 100
 In-hospital death (%) 0
Reperfusion 
pattern
I (n=204) II (n=11) III (n=133) IV (n=41) V (n=122) VI (n=74)
% pts with 
complete ST 
resolution
37.3 † 36.4 † 45.9 † 60.9 † 52.5 † 72.9 †
AUC [U/lxh] 3690±1840 3870±1975 2485±882* 2340±837** 2259±954* 2115±810**
EF-24h [%] 42 ±11 † 41±3 † 46±9 † 45±12 † 53±9 † 55±8 †
EF-6m [%] 39±10†,*** 40±3 † 45±8 † 46±12 † 55±9 †,†† 59±9†,***
*p<0,01 vs. I, **p<0,01 vs. II, †p<0,001 among I-VI; ††p<0,001 vs. I-IV; ***p<0,01 vs. 
EF-24h
Hyperglycemia (+)
(n=35)
Hyperglycemia (-)
(n=71)
P value
SFR, % 63 24 <0.0001
DDT, ms 393±282 704±369 <0.0001
CFR 1.3±0.5 1.6±0.4 0.004
Peak CPK, IU/l 6099±2686 3735±2376 <0.0001
LVEF at 3 weeks, % 48±14 58±12 0.0003
ST Variables and Outcomes for Lytics and Stenting Therapy Groups
Variable MACE
Stent
No MACE
Stent
P value MACE
Lytics
No MACE
Lytics
P value
STABLE 132 81 .003 186 92 <.001
>70%ST 52.8 70.0 .006 42.0 65.1 <.001
AREA 8,837 5,654 .023 8,060 5,000 .011
LATE 23.9 9.2 .004 38.6 13.4 <.001
